Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $8

Morgan Stanley analyst Matthew Harrison maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $10 to $8.
byBenzinga Newsdesk
November 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Morgan Stanley analyst Matthew Harrison maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $10 to $8.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0